Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhisuixin is a Traditional Chinese Medicine (TCM) granule formulation developed by The Affiliated Brain Hospital of Guangzhou Medical University. It is currently being investigated for the treatment of subthreshold depression in adolescents. The drug is evaluated in clinical trials for its efficacy and safety in improving a range of symptoms, including depressive mood, anxiety, sleep disturbances, fatigue, and cognitive impairment. As a multi-component herbal intervention, Zhisuixin is designed to address the complex pathophysiology of early-stage depressive disorders, and ongoing research aims to identify specific mechanistic biomarkers associated with its therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhisuixin.